HP
BTAI icon

Hound Partners’s BioXcel Therapeutics BTAI Stock Holding History

Hound Partners’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,188
Closed -$782K – 55
2020
Q1 		$782K Buy
+2,188
New +$786K 0.07% 35

Other funds holding BTAI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Hound Partners's BTAI Position: Q2 2020 in Review

Hound Partners sold out of BioXcel Therapeutics (BTAI) in Q2 2020, closing a stake of 2,188 shares — an estimated $782K sold.

Hound Partners first reported a position in BTAI in Q1 2020 and held it in 1 quarter. The position peaked at $782K in Q1 2020. 104 funds tracked by Wall St. Rank hold BTAI as of Q2 2020.

  • Hound Partners reported no remaining BioXcel Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Hound Partners sold 2,188 BioXcel Therapeutics shares in Q2 2020, an estimated $782K.
  • Hound Partners first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 1 quarter.
  • Hound Partners's BioXcel Therapeutics position peaked at $782K in Q1 2020.
  • 104 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2020.

Based on Hound Partners's 13F filing for Q2 2020, filed 14 Aug 2020.